PPARG and neoplasm: A 2011 study showed that the combination of TZD and the demethylating drug hydralazine could upregulate PPARγ transcriptional and translational levels in triple-negative breast cancer (TNBC) cells, thereby promoting the anti-proliferative and apoptotic effects of TNBC cells and reducing the xenograft tumor growth proliferation index [202].